

ASX RELEASE

ADMEDUS TO HOST INVESTOR WEBINAR

- Admedus investor webinar Monday, 11 July 2016
- 11am AEST Sydney/Melbourne/Brisbane time; 9am AWST Perth time

Brisbane, Australia 6 July 2016

Admedus (ASX:AHZ) has today announced that it will hold an investor webinar on Monday, 11 July 2016 to discuss the results of the recent Company review, and will provide clear direction for the Company over the next 12 months.

The review and associated restructuring initiatives are designed to address issues such as costs, commercial performance and strategic priorities, as well as to accelerate the Company's path to profitability.

Management and the Board of Directors have reviewed the following:

- Company Strategy;
- Commercial Operations;
- Global Organisational Structure;
- Global Financial review (targeting OPEX reductions);
- Clinical and R&D programs; and
- Manufacturing (targeting yield and cost improvements).

The webinar will be live and investors are welcome to submit questions in the lead up to the webinar to Chief Operating Officer, Julian Chick info@admedus.com

Webinar details

Date: Monday, 11 July 2016

Time: 11am AEST Sydney/Melbourne/Brisbane time; 9am AWST Perth time

Please register to attend the webinar at:

<https://attendee.gotowebinar.com/register/4052131732528351748>

Once you have registered to attend the webinar via the link above, you will receive a confirmation email with the webcast link and dial-in details.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com